Abstract library

16 results for "neoadjuvant PRRT".
#665 Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Surgery is the only potential for cure in patients with pancreatic neuroendocrine tumors (pNETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Esther I Van Vliet
#290 Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)
Introduction: Neoadjuvant treatment is used as pre-surgical therapy in different cancers to decrease tumor size. PRRT can be a useful tool in neoadjuvant treatment of patients with well-differentiated NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anna Sowa-Staszczak
#1863 Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis
Introduction: Neoadjuvant Peptide receptor radionuclide therapy (NPRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNEN) before surgery. Is not clear if NPRRT increases postoperative morbidity
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Francesca Muffatti
#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETS Conference (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Noémie S Minczeles
#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETS Conference (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#515 Neuroendocrine Carcinomas (NEC) of the Pancreas: A Land of Hope?
Introduction: Poorly differentiated neuroendocrine carcinomas (NEC) of the pancreas are historically associated with poor prognosis. Contemporary data regarding their treatment and survival are scant.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Letizia Boninsegna
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#1558 Multivisceral Transplantation and Vascularised Sentinel Forearm Flap for a Metastatic Gut-Derived Neuroendocrine Tumour: Follow-up
Introduction: We previously reported the first documented case of a novel approach in a patient with extensive mesenteric metastases from a small bowel (SB) NET: this combined multivisceral transplantation (MVT) and a vascularised sentinel forearm flap (VSFF) from the same donor.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
Authors: Clift A, Giele H, Vrakas G, Reddy S, ...
#1776 External Beam Radiotherapy (EBRT) in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review
Introduction: EBRT is infrequently used to treat GEPNETS.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Thompson R, Lam M, Pavlakis N, ...
Keywords: EBRT, review
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team